ImmunityBio Inc (NASDAQ:IBRX) traded at $3.01 at close of the session on Monday, March 31 and made a downward move of -4.14% on its previous day’s price.
Looking at the stock we see that its previous close was $3.14 and the beta (5Y monthly) reads -0.183 with the day’s price range being $2.92 – $3.1499. In terms of its 52-week price range, IBRX has a high of $10.53 and a low of $2.28. The company’s stock has lost about -8.51% over that past 30 days.
ImmunityBio Inc has a market cap of $2.57 billion and is expected to release its quarterly earnings report on 2025-Mar-02.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at 17.5M, with a low of 13.78M and a high of 19.74M. The median projection represents growth squeezing down to 43,644.38% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for current year is expected to hit 105.24M, or 613.74% up from figures reported last year.
On the other hand, looking at the outlook for the IBRX stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 100% Sell.
Based on estimates by 1 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 0 have rated the ImmunityBio Inc (IBRX) stock as a Hold, while 0 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 1 suggest the stock as a Sell. The stock has an overall rating of Sell and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is 3.33% off its SMA20 and -3.38% from its 50-day simple moving average. The RSI (14) is pointing at 50.60 while the volatility over the past week is 10.84% and jumps to 8.18% over the past one month. The beta value is 0.39, while the average true range (ATR) is currently pointing at 0.26. The average price target for the stock over the next 12 months is $6, with the estimates having a low of $6 and a high of $6. These price ends are -99.34% and -99.34% off the current price level respectively, although investors could be excited at the prospect of a -99.34% if the IBRX share price touches on the median price of $6.
Coming back to ImmunityBio Inc (NASDAQ:IBRX), we note that the average 3-month trading volume was 6.16 million, while that of the preceding 10-day period stands at 6.6 million. Current shares outstanding are 852.74 million.
The insiders hold 89.60% of the company’s shares while institutions hold 9.90%. The data shows that short shares as of 2025-03-14, stood at 59.54 million at a short ratio of 9.03. This represents a 1871.00 short interest in shares outstanding on 2025-03-14. Shares short rose in March from the previous month at 56.96 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock 17.58% up in year-to-date price movement.
